AEON Biopharma, Inc.(AEON)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 24 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AEON Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for AEON Biopharma, Inc. (AEON), a Healthcare sector company. AEON is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 24 institutional filers currently hold this stock. Top institutional holders of AEON by reported 13-F value include Dauntless Investment Group, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. AEON trades on the NYSE exchange and files with the SEC under CIK 1837607. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AEON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AEON Biopharma, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-1.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-193.4% YoYOperating Income
-117.5% YoYEPS (Diluted)
-202.9% YoYTotal Assets
+77.0% YoYOp. Cash Flow
+14.7% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-39.2M -193.4% | $42.0M | — | $-52.6M -740.9% | $8.2M | — |
| Operating Income | $-12.8M -117.5% | $73.0M | — | $-48.4M -2401.6% | $-1.9M | — |
| EPS (Diluted) | $-3.95 -202.9% | $3.84 | — | $-0.38 | — | — |
| Total Assets | $5.6M +77.0% | $3.1M -54.1% | $6.8M -36.5% | $10.8M -96.1% | $276.9M +341813.0% | $81.0K |
| Operating Cash Flow | $-17.3M +14.7% | $-20.3M | — | $-35.6M -2280.5% | $-1.5M | — |
| Free Cash Flow | $-17.3M | — | — | $-35.9M | — | — |
Get alerted when AEON's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for AEON Biopharma, Inc. including:
Top Institutional Holders of AEON
Dauntless Investment Group, LLC
$9.0M12,490,154 shGEODE CAPITAL MANAGEMENT, LLC
$68.6K95,311 shVANGUARD CAPITAL MANAGEMENT LLC
$65.1K90,529 shBlue Owl Capital Holdings LP
$30.5K42,353 shFormidable Asset Management, LLC
$19.7K20,024 shStoneX Group Inc.
$14.9K18,953 shVANGUARD FIDUCIARY TRUST CO
$9.9K13,713 shLPL Financial LLC
$8.3K11,507 shCITIGROUP INC
$5.3K7,315 shUBS Group AG
$3.6K5,062 sh
| Fund | Value | Shares |
|---|---|---|
| Dauntless Investment Group, LLC | $9.0M | 12,490,154 |
| GEODE CAPITAL MANAGEMENT, LLC | $68.6K | 95,311 |
| VANGUARD CAPITAL MANAGEMENT LLC | $65.1K | 90,529 |
| Blue Owl Capital Holdings LP | $30.5K | 42,353 |
| Formidable Asset Management, LLC | $19.7K | 20,024 |
| StoneX Group Inc. | $14.9K | 18,953 |
| VANGUARD FIDUCIARY TRUST CO | $9.9K | 13,713 |
| LPL Financial LLC | $8.3K | 11,507 |
| CITIGROUP INC | $5.3K | 7,315 |
| UBS Group AG | $3.6K | 5,062 |
More Healthcare Companies
View all Healthcare →Put AEON on your watchlist
Track score changes the day AEON Biopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AEON a good stock to buy?
13F Pro's AI-powered analysis of AEON Biopharma, Inc. (AEON) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AEON are available on the AEON stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AEON is classified as a small company.
Which hedge funds own AEON?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AEON. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AEON Biopharma, Inc.'s investment landscape.